54

 

High-Throughput Sequencing of Bacterial Artificial Chromosomes and Genomic DNA--Fidelity Systems, Inc., 7961 Cessna Avenue, Gaithersburg, MD  20879-4117; 301-527-0804

Dr. Sergei Kozyavkin, Principal Investigator

Dr. Andrei Malykh, Business Official

DOE Grant No. DE-FG02-00ER83009

Amount:  $100,000

 

Wide use of the shotgun DNA sequencing method for the acquisition of draft data is not followed by the equally productive finishing technology.  We have recently combined our proprietary biochemical and chemical approaches and showed feasibility of rapid finishing of draft human BAC projects with 2.3x-4.5x coverage to the high quality and contiguity standards.  Development of high throughput technology based on our methods will transform the art of finishing genome projects into a streamlined production operation.  Our objective is the development of advanced DNA sequencing reagents and protocols that are 100 to 1,000 times more efficient than the current standards and apply them for the sequencing directly off BAC and genomic DNA templates.  We will design a model for the optimization of the overall workflow in the high throughput environment and test it on the ongoing genomics projects.  In Phase I we will demonstrate feasibility of our approach to multiply the yield of sequencing reactions.  We will show how the advanced chemistry will simplify massive sequencing of BAC and microbial genomic DNA and make direct sequencing of larger genomes possible. We will also develop a new solution for sample tracking and internal control.

 

Commercial Applications and Other Benefits as described by the awardee:  Rapid and cost effective finishing of genome projects will fulfill unmet demand in academic and government projects and booming biotechnology industry.  It will free genomics centers and companies from unproductive work and accelerate overall rate of data acquisition.  Streamlined sequencing directly off genomic DNA without cloning or PCR steps will find wide applications in functional and comparative genomics.